Literature DB >> 18831887

Rat parathyroid hormone 1-34 signals through the MEK/ERK pathway to induce cardiac hypertrophy.

X Liu1, R Xie, S Liu.   

Abstract

This study aimed to characterize the role of the mitogen-activated protein kinase (MAPK) kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway in cardiac hypertrophy induced by parathyroid hormone (PTH). Various concentrations of rat PTH1-34 were used to induce hypertrophy in neonatal rat ventricular cardiomyocytes, and the effects were compared with control cells and those treated with PD98059, a selective inhibitor of MEK1. Hypertrophy was assessed in terms of cell diameter, atrial natriuretic peptide (ANP) mRNA expression and protein synthesis; the MEK/ERK pathway was assessed by measuring levels of phosphorylated ERK1/2. Treatment with PTH1-34 at 100 nM for 24 h effectively induced cardiac hypertrophy (increased cell diameter, protein synthesis and ANP mRNA expression) and also increased levels of phosphorylated ERK1/2 compared with normal control cells. Treatment with PTH1-34 plus PD98059 significantly attenuated these changes. These results demonstrate that inhibition of the MEK/ERK pathway blocks PTH1-34-induced cardiac hypertrophy, suggesting that PTH1-34 might signal through the MAPK pathway to induce hypertrophy in cardiomyocytes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18831887     DOI: 10.1177/147323000803600510

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  7 in total

1.  Nardosinone protects H9c2 cardiac cells from angiotensin II-induced hypertrophy.

Authors:  Meng Du; Kun Huang; Lu Gao; Liu Yang; Wen-Shuo Wang; Bo Wang; Kai Huang; Dan Huang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-12-13

2.  Parathyroid hormone promotes osteoblastic differentiation of endothelial cells via the extracellular signal-regulated protein kinase 1/2 and nuclear factor-κB signaling pathways.

Authors:  Zhi-Yuan Cheng; Ting Ye; Qiu-Yang Ling; Ting Wu; Gang-Yong Wu; Gang-Jun Zong
Journal:  Exp Ther Med       Date:  2017-11-23       Impact factor: 2.447

3.  Evaluation of left ventricle functions by tissue Doppler, strain, and strain rate echocardiography in patients with primary hyperparathyroidism.

Authors:  Didem Ozdemir; Gulhan Yuksel Kalkan; Nihal Akar Bayram; Eda Demir Onal; Reyhan Ersoy; Engin Bozkurt; Bekir Cakir
Journal:  Endocrine       Date:  2014-03-28       Impact factor: 3.633

4.  Novel markers of left ventricular hypertrophy in uremia.

Authors:  Hironori Nakamura; Masanori Tokumoto; Masahide Mizobuchi; Cynthia S Ritter; Jane L Finch; Masanori Mukai; Eduardo Slatopolsky
Journal:  Am J Nephrol       Date:  2010-01-30       Impact factor: 3.754

5.  Original Research: Atorvastatin prevents rat cardiomyocyte hypertrophy induced by parathyroid hormone 1-34 associated with the Ras-ERK signaling.

Authors:  Xiaogang Liu; Chunbo Zou; Chengyuan Yu; Rujuan Xie; Manshu Sui; Suhong Mu; Li Li; Shilei Zhao
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-10

Review 6.  Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment.

Authors:  Luca Di Lullo; Antonio Gorini; Domenico Russo; Alberto Santoboni; Claudio Ronco
Journal:  Cardiorenal Med       Date:  2015-07-15       Impact factor: 2.041

7.  Serum uric acid is associated with left ventricular hypertrophy independent of serum parathyroid hormone in male cardiac patients.

Authors:  Shu-ichi Fujita; Yusuke Okamoto; Kensaku Shibata; Hideaki Morita; Takahide Ito; Koichi Sohmiya; Masaaki Hoshiga; Nobukazu Ishizaka
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.